Additionally, Xu et al. reported a novel ALK-targeting HyT degrader (29) that overcomes E3 ligase-dependent drug resistance, enabling efficient degradation of ALK in drug-resistant tumor models (Xie et al., 2025). This evidence concerns the gene ALK and neoplasm.